Tight regulation of foreign genes expressed in vivo would facilitate studies of many biologic processes and would be useful for gene transfer-based therapies. To test the ability of a tetracycline-regulated gene expression system to function in vivo, we directly injected chimeric tet repressor-VP16 transactivator expression plasmids and luciferase target genes into the hearts of adult rats. Cardiac luciferase activity increased over two orders of magnitude in response to small changes in input tetracycline-controlled transactivator DNA. Transactivation was repressed to background levels by subtherapeutic concentrations of tetracycline in a dose-dependent manner. Target gene expression could be rapidly and reversibly controlled by manipulating antibiotic administration. This system may be particularly useful for in vivo studies of gene function or gene therapies where the timing or extent of expression are critical variables. (J. Clin. Invest. 1994.93:1864-1868
Introduction
The ability to tightly and reversibly control the expression of exogenous genetic elements in vivo would find great utility in studies of gene function as well as in DNA-based gene therapies. External signals could modulate the accumulation of expressed proteins, enabling one to assess their function at varying concentrations or during specific time intervals. Protein abundance could also be regulated to meet specific therapeutic needs. Despite these potential benefits, highly regulated expression of foreign DNA sequences in vivo remains problematic.
The tetracycline resistance operon of Escherichia coli has been exploited to design a highly effective transcriptional regulatory system in cultured mammalian cells ( 1) . A chimeric transactivator, designated tetracycline-controlled transactivator (tTA),' consisting of the DNA and tetracycline binding domains from the bacterial tet repressor (tetR) fused to the 1. Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; CMV, cytomegalovirus; tetO, tet operator; tetR, tet receptor; tTA, tetracycline-controlled transactivator; VP 16 , virion protein 16. transactivation domain of herpes simplex virion protein 16 (VP 16), markedly stimulates transcription from minimal promoters harboring tet operator (tetO) sequences. By virtue ofits affinity for tetR, tetracycline competitively inhibits tTA-dependent transactivation.
In this study, we tested the functionality of this system in vivo by directly transferring plasmid DNAs into the hearts of adult rats and studying their behavior in response to systemic tetracycline therapy. The direct cardiac injection technique has recently been shown to specifically transfect cardiac myocytes surrounding the site of DNA injection (2) . Here we demonstrate that transcription of target genes harboring tetO sequences can be markedly transactivated by coinjected tTA expression plasmids. The level oftransactivation can be regulated over several orders of magnitude by systemic therapy with oral tetracycline. Furthermore, the extent of target gene expression can be rapidly and reversibly controlled by manipulating antibiotic treatment.
Methods
DNA plasmids. The tTA expression plasmids used in this study included pUHD1 5-1 and pa-tTA, as shown in Fig. 1 . pUHD1 5-1 contains regulatory sequences from the cytomegalovirus (CMV) promoter and enhancer and directs constitutive expression of tTA, as previously described ( 1). The cardiac-specific pa-tTA includes regulatory elements (-613 to +32, relative to transcription initiation) from the rat alpha myosin heavy chain gene (3), a heterologous adenoviral-immunoglobulin splice cassette, an EcoRI-BamHI fragment containing the tTA coding region from pUHD15-1 ( 1 ) , and a BglII-EcoRI fragment from the human growth hormone gene which includes the polyadenylation signals and 3' flanking sequence (4) . pUHC1 3-3 has been described previously, and places the firefly luciferase reporter gene downstream of the chimeric tet operon/CMV minimal promoter (1) . pRSVCAT expresses chloramphenicol acetyltransferase (CAT) from the Rous sarcoma virus long terminal repeat (5) and was included in all injections to normalize for transfection efficiency.
Plasmid DNAs were constructed and verified according to standard techniques (6) . Large-scale plasmid preparations were purified by column chromatography (Qiagen, Inc., Chatsworth, CA), according to the manufacturer's protocol.
Cardiac gene transfer. Cardiac gene transfer was carried out essentially as described previously (7) . All studies were carried out using 175-200-g female Wistar rats, which were cared for in accordance with a protocol approved by the Institutional Animal Care and Use Committee. In brief, animals were anesthetized with an intraperitoneal injection of 4% nose cone fitted over the snout of the rat (small anir Harvard Apparatus, Inc., South Natick, MA). The ste closed, and the animals were allowed to recover. Mort; procedure was < 10%.
Reporter gene assays. Animals were killed at vario gene transfer, and their hearts were rapidly removed ice-cold PBS. Excess connective tissue, atria, and the bast cles were discarded. The remaining ventricular tissue nized, and luciferase and CAT assays were performed 1 lysate exactly as described previously (7) . Luciferase actii mined using a luminometer (Monolight 2010; Analyti cence Laboratory, San Diego, CA). CAT thin-layer ch were recorded with a phosphor-storage screen, and perce conversion was visualized and quantified using a Phospi associated software (Molecular Dynamics, Inc., Sunnyv each heart, normalized luciferase activity was determined erase activity -background)/% CAT conversion, as I scribed (7).
Tetracycline administration. For oral therapy, tetra( chloride (Sigma Immunochemicals, St. Louis, MO) was 0.1 g/ml stock in 50% ethanol and was diluted to the fil tion with 2.5% sucrose in water. For parenteral therap dine (LA200; Pfizer Inc., New York) was diluted to 14 water, and 300 Ml was injected intraperitoneally. No ot fects due to antibiotic therapy were observed.
Tetracycline-dependent repression. 2 d before cardiac drinking water was replaced with 2.5% sucrose containin 0.1 mg/ml tetracycline hydrochloride or vehicle alone injected with pa-tTA (5 jig), pUHCl 3-3 (5Mgg), and pR' and harvested 5 d later for determination of luciferase an ties.
Kinetic analysis oftetracycline-regulated expression.
the time course of repression, 40 rats underwent direct transfer with pa-tTA, pUHC1 3-3, and pRSVCAT. 5 d animals were randomly chosen to receive antibiotic t pressed group) or vehicle alone (control group). Anin pressed group received a single dose of oxytetracycline (3 toneally) and were started on oral tetracycline therapy (1 drinking water). At subsequent time points, hearts fror hGH polyA animals from each group were harvested, and normalized luciferase a~I activity was determined. Tetracycline-regulated Cardiac Gene Expression In Vivo 1865
luciferase units, a value twofold greater (P = 0.007) than that seen with the same amount of the pa-tTA DNA ( 152,139±6,073, n = 4) and not statistically different from that obtained with 10 ,ug of the cardiac-specific transactivator (281,618±39,688, n = 4). Inhibition of transactivation by oral tetracycline therapy.
We next evaluated whether tTA-dependent reporter gene activity could be inhibited by systemic therapy with tetracycline. Based upon the initial set of experiments, all injections included pa-tTA (5 ,ug), pUHC13-3 (5 gtg), and pRSVCAT (2 .ug). Beginning 48 h before cardiac gene transfer and continuing until the time of killing, drinking water was replaced with 2.5% sucrose containing either 1.0 or 0.1 mg/ml tetracycline or vehicle alone. Transactivation ofthe target gene was markedly repressed by oral antibiotic therapy, as shown in Fig. 3 . As little as 0.1 mg/ml tetracycline added to the drinking water commencing 2 d before cardiac injection reduced luciferase activity by 90%, compared with vehicle alone (P < 0.001). Tetracycline at 1 mg/ml reduced activity by 97% (P < 0.001 ), comparable with levels obtained in the absence of the transactivator. Kinetic analysis oftetracycline-regulated gene expression. The ability to repress or induce target gene expression and the time course ofsuch regulation were also assessed. To determine the rapidity with which transcription could be repressed, systemic tetracycline levels were increased rapidly by treating rats with the parenteral tetracycline analogue, oxytetracycline. As shown in Fig. 4 A, untreated control animals showed a gradual time-dependent fall in normalized luciferase activity, consistent with the transient nature ofthis gene transfer technique. In contrast, animals receiving oxytetracycline showed a rapid reduction in normalized luciferase activity, which declined by 60% 24 h after initiating antibiotic treatment (P < 0.01 ) and fell to baseline levels by 48 h.
Conversely, repression of tTA-dependent transactivation was reversed rapidly after discontinuing tetracycline therapy. Tetraycline Dosage (mg/ml) Figure 3 . Tetracycline-dependent repression in vivo. 2 d before cardiac injection, the drinking water was replaced with 2.5% sucrose containing either 0 (n = 6), 0.1 (n = 5), or 1.0 mg/ml (n = 6) tetracycline hydrochloride, which was continued until killing. All animals were injected with pa-tTA (5 ,ug), pUHC13-3 (5 Mig), and pRSVCAT (2 Mg). 5 d later, normalized luciferase activity was determined as above. Each data point represents the mean±SE. Compared with animals receiving no antibiotic, normalized luciferase activity was repressed in a dose-dependent manner with both 0.1 (P < 0.005) or 1.0 mg/ml (P < 0.001 ) tetracycline hydrochloride.
As shown in Fig. 4 B, 24 h after removing a submaximally inhibitory dose (0.1 mg/ml) of tetracycline from the drinking water, reporter gene activity had increased 2.5-fold and was fully induced by 60 h (P < 0.0001 ).
To account for time-dependent changes in reporter gene activity associated with the gene-transfer technique, ratios of normalized luciferase activity in the experimental groups (repressed or induced) to those observed in the respective control groups were derived at each time point. The temporal profile of tetracycline-regulated gene repression and induction achieved in vivo were then compared directly, as shown in Fig. 4 C. In both cases, substantial modulation ofgene expression was evident within 24 h after manipulating antibiotic therapy and approached new steady state levels within about 48 h.
Discussion
In this report, we have demonstrated the feasibility ofachieving highly regulated transcriptional control of foreign genes introduced in vivo. First, we have shown that a chimeric protein (tTA), consisting of the DNA and antibiotic binding domains from the tetR protein fused to the transactivation domain of herpes simplex VP 16, can successfully transactivate a reporter gene harboring tetO sequences in vivo. Second, we have demonstrated that oral therapy with tetracycline can regulate effectively the extent of transactivation over several orders of magnitude. Finally, we have defined the time course of target gene induction and repression in response to tetracycline treatment and have shown that this process is relatively rapid.
Few mechanisms for controlling gene expression in vivo have been described, and to date none have demonstrated the temporal and quantitative regulation characteristic of the tTA system. Binary transgenic approaches, in which transactivator strains of mice harboring the yeast GAL4 protein are crossed with second strains harboring a GAL4-inducible target gene, have recently been described (8) . In progeny carrying both transgenes, the normally silent target gene was activated by the presence of the transactivator. Although target gene activation in compound hemizygous offspring could be specifically activated, the extent oftransactivation was not responsive to external regulation. Approaches based upon the Drosophila ecdysone receptor have also been proposed for regulated expression of target genes, however, to date only in vitro studies have been reported (9) . By fusing the ligand-binding domain ofthe insect hormone receptor to the DNA-binding domain of heterologous transcription factors, hormone-dependent transcription of reporter genes flanked by ecdysone response elements was demonstrated. Target gene expression in vitro could be induced -50-fold by the addition ofmicromolar concentrations of muristerone A. Finally, modified proteins derived from the lac repressor have also been constructed which transactivate target genes harboring lac operator sequences. The lacd activator protein LAP267, containing the transactivation domain of herpes simplex virus VP 16 inserted into the lac repressor, results in a temperature-and isopropyl-f,-D-thiogalactopyranoside-sensitive transactivator. Although selected cell lines showed induction of target gene expression up to 1,200-fold, the requirement for stringent temperature control and millimolar concentrations of isopropyl-f3-D-thiogalactopyranoside is potentially problematic for in vivo use (10) .
The in vivo regulatory system described in this report uses derivatives of polycyclic naphthacenecarboxamides ( 11 
